Elite Pharmaceuticals appoints Robert Chen as CFO effective May 16, 2022, replacing Marc Bregman

ELITE PHARMACEUTICALS INC /NV/

Robert Chen named CFO; base salary $250,000/year; at-will employment starting May 16, 2022.
Chen receives stock options for 900,000 shares, vesting over 3 years from issuance.
Prior CFO Marc Bregman ceased services as Secretary and Treasurer effective April 29, 2022.
Chen brings 20+ years life science finance experience, most recently VP Finance at KBP Biosciences.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Chen

Chief Financial Officer

ELTP · ELITE PHARMACEUTICALS INC /NV/

Effective: 2022-05-16
Filed: May 11, 2022, 7:59 PM ET

On May 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Robert Chen to serve as the Registrants’ Chief Financial Officer, replacing Marc Bregman, who served as the Registrant’s Chief Financial Officer effective May 16, 2022.

Departed

Marc Bregman

Chief Financial Officer

ELTP · ELITE PHARMACEUTICALS INC /NV/

Effective: 2022-05-16
Successor: Robert Chen
Filed: May 11, 2022, 7:59 PM ET

Effective as of May 16, 2022, Mr. Chen replaced Mr. Bregman as the Registrant’s Chief Financial Officer, and Mr. Bregman, who also served as the Registrant’s Secretary and Treasurer, ceased providing services to the Registrant in such capacities as of April 29, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Chen was appointed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On May 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Robert Chen to serve as the Registrants’ Chief Financial Officer, replacing Marc Bregman, who served as the Registrant’s Chief Financial Officer effective May 16, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Bregman departed as Chief Financial Officer at ELITE PHARMACEUTICALS INC /NV/.

Action: replaced
Role: Chief Financial Officer

Exact text from the filing

Effective as of May 16, 2022, Mr. Chen replaced Mr. Bregman as the Registrant’s Chief Financial Officer, and Mr. Bregman, who also served as the Registrant’s Secretary and Treasurer, ceased providing services to the Registrant in such capacities as of April 29, 2022.

View on SEC.gov

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-22-012876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.